IBDEI1F7 ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,22975,1,3,0)
;;=3^Purpura,Hemorrhagic Condition
;;^UTILITY(U,$J,358.3,22975,1,4,0)
;;=4^D69.8
;;^UTILITY(U,$J,358.3,22975,2)
;;=^88074
;;^UTILITY(U,$J,358.3,22976,0)
;;=L08.9^^76^992^28
;;^UTILITY(U,$J,358.3,22976,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22976,1,3,0)
;;=3^Pyoderma
;;^UTILITY(U,$J,358.3,22976,1,4,0)
;;=4^L08.9
;;^UTILITY(U,$J,358.3,22976,2)
;;=^5009082
;;^UTILITY(U,$J,358.3,22977,0)
;;=L01.00^^76^992^29
;;^UTILITY(U,$J,358.3,22977,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22977,1,3,0)
;;=3^Impetigo
;;^UTILITY(U,$J,358.3,22977,1,4,0)
;;=4^L01.00
;;^UTILITY(U,$J,358.3,22977,2)
;;=^5008938
;;^UTILITY(U,$J,358.3,22978,0)
;;=L03.90^^76^992^30
;;^UTILITY(U,$J,358.3,22978,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22978,1,3,0)
;;=3^Cellulitis
;;^UTILITY(U,$J,358.3,22978,1,4,0)
;;=4^L03.90
;;^UTILITY(U,$J,358.3,22978,2)
;;=^5009067
;;^UTILITY(U,$J,358.3,22979,0)
;;=Z79.1^^76^992^31
;;^UTILITY(U,$J,358.3,22979,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22979,1,3,0)
;;=3^Long Term Use NSAID/Oth Health Status
;;^UTILITY(U,$J,358.3,22979,1,4,0)
;;=4^Z79.1
;;^UTILITY(U,$J,358.3,22979,2)
;;=^5063332
;;^UTILITY(U,$J,358.3,22980,0)
;;=Z79.899^^76^992^32
;;^UTILITY(U,$J,358.3,22980,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22980,1,3,0)
;;=3^Long Term Use Oth Drug
;;^UTILITY(U,$J,358.3,22980,1,4,0)
;;=4^Z79.899
;;^UTILITY(U,$J,358.3,22980,2)
;;=^5063343
;;^UTILITY(U,$J,358.3,22981,0)
;;=Z80.8^^76^992^33
;;^UTILITY(U,$J,358.3,22981,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22981,1,3,0)
;;=3^Family Hx of Melanoma
;;^UTILITY(U,$J,358.3,22981,1,4,0)
;;=4^Z80.8
;;^UTILITY(U,$J,358.3,22981,2)
;;=^5063356
;;^UTILITY(U,$J,358.3,22982,0)
;;=Z48.817^^76^992^34
;;^UTILITY(U,$J,358.3,22982,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22982,1,3,0)
;;=3^Surgical Aftercare Skin/Subcutaneous Tissue
;;^UTILITY(U,$J,358.3,22982,1,4,0)
;;=4^Z48.817
;;^UTILITY(U,$J,358.3,22982,2)
;;=^5063054
;;^UTILITY(U,$J,358.3,22983,0)
;;=R99.^^76^992^35
;;^UTILITY(U,$J,358.3,22983,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22983,1,3,0)
;;=3^Dead Unknown Mortality
;;^UTILITY(U,$J,358.3,22983,1,4,0)
;;=4^R99.
;;^UTILITY(U,$J,358.3,22983,2)
;;=^5019750
;;^UTILITY(U,$J,358.3,22984,0)
;;=Z85.9^^76^992^36
;;^UTILITY(U,$J,358.3,22984,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22984,1,3,0)
;;=3^Personal Hx of Unspec Neoplasm/Cancer
;;^UTILITY(U,$J,358.3,22984,1,4,0)
;;=4^Z85.9
;;^UTILITY(U,$J,358.3,22984,2)
;;=^5063452
;;^UTILITY(U,$J,358.3,22985,0)
;;=C79.9^^76^992^37
;;^UTILITY(U,$J,358.3,22985,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22985,1,3,0)
;;=3^Metastatic Cancer Unspec
;;^UTILITY(U,$J,358.3,22985,1,4,0)
;;=4^C79.9
;;^UTILITY(U,$J,358.3,22985,2)
;;=^5133344
;;^UTILITY(U,$J,358.3,22986,0)
;;=Q3014^^77^993^1^^^^1
;;^UTILITY(U,$J,358.3,22986,1,0)
;;=^358.31IA^3^2
;;^UTILITY(U,$J,358.3,22986,1,2,0)
;;=2^Q3014
;;^UTILITY(U,$J,358.3,22986,1,3,0)
;;=3^Telehealth Fac Fee-Pt Site
;;^UTILITY(U,$J,358.3,22987,0)
;;=B19.10^^78^994^1
;;^UTILITY(U,$J,358.3,22987,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22987,1,3,0)
;;=3^Hepatitis B w/o Hepatic Coma
;;^UTILITY(U,$J,358.3,22987,1,4,0)
;;=4^B19.10
;;^UTILITY(U,$J,358.3,22987,2)
;;=^5000552
;;^UTILITY(U,$J,358.3,22988,0)
;;=B17.10^^78^994^2
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1F7 3746 printed Sep 15, 2024@21:31:46 Page 2
IBDEI1F7 ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,22975,1,3,0)
+2 ;;=3^Purpura,Hemorrhagic Condition
+3 ;;^UTILITY(U,$J,358.3,22975,1,4,0)
+4 ;;=4^D69.8
+5 ;;^UTILITY(U,$J,358.3,22975,2)
+6 ;;=^88074
+7 ;;^UTILITY(U,$J,358.3,22976,0)
+8 ;;=L08.9^^76^992^28
+9 ;;^UTILITY(U,$J,358.3,22976,1,0)
+10 ;;=^358.31IA^4^2
+11 ;;^UTILITY(U,$J,358.3,22976,1,3,0)
+12 ;;=3^Pyoderma
+13 ;;^UTILITY(U,$J,358.3,22976,1,4,0)
+14 ;;=4^L08.9
+15 ;;^UTILITY(U,$J,358.3,22976,2)
+16 ;;=^5009082
+17 ;;^UTILITY(U,$J,358.3,22977,0)
+18 ;;=L01.00^^76^992^29
+19 ;;^UTILITY(U,$J,358.3,22977,1,0)
+20 ;;=^358.31IA^4^2
+21 ;;^UTILITY(U,$J,358.3,22977,1,3,0)
+22 ;;=3^Impetigo
+23 ;;^UTILITY(U,$J,358.3,22977,1,4,0)
+24 ;;=4^L01.00
+25 ;;^UTILITY(U,$J,358.3,22977,2)
+26 ;;=^5008938
+27 ;;^UTILITY(U,$J,358.3,22978,0)
+28 ;;=L03.90^^76^992^30
+29 ;;^UTILITY(U,$J,358.3,22978,1,0)
+30 ;;=^358.31IA^4^2
+31 ;;^UTILITY(U,$J,358.3,22978,1,3,0)
+32 ;;=3^Cellulitis
+33 ;;^UTILITY(U,$J,358.3,22978,1,4,0)
+34 ;;=4^L03.90
+35 ;;^UTILITY(U,$J,358.3,22978,2)
+36 ;;=^5009067
+37 ;;^UTILITY(U,$J,358.3,22979,0)
+38 ;;=Z79.1^^76^992^31
+39 ;;^UTILITY(U,$J,358.3,22979,1,0)
+40 ;;=^358.31IA^4^2
+41 ;;^UTILITY(U,$J,358.3,22979,1,3,0)
+42 ;;=3^Long Term Use NSAID/Oth Health Status
+43 ;;^UTILITY(U,$J,358.3,22979,1,4,0)
+44 ;;=4^Z79.1
+45 ;;^UTILITY(U,$J,358.3,22979,2)
+46 ;;=^5063332
+47 ;;^UTILITY(U,$J,358.3,22980,0)
+48 ;;=Z79.899^^76^992^32
+49 ;;^UTILITY(U,$J,358.3,22980,1,0)
+50 ;;=^358.31IA^4^2
+51 ;;^UTILITY(U,$J,358.3,22980,1,3,0)
+52 ;;=3^Long Term Use Oth Drug
+53 ;;^UTILITY(U,$J,358.3,22980,1,4,0)
+54 ;;=4^Z79.899
+55 ;;^UTILITY(U,$J,358.3,22980,2)
+56 ;;=^5063343
+57 ;;^UTILITY(U,$J,358.3,22981,0)
+58 ;;=Z80.8^^76^992^33
+59 ;;^UTILITY(U,$J,358.3,22981,1,0)
+60 ;;=^358.31IA^4^2
+61 ;;^UTILITY(U,$J,358.3,22981,1,3,0)
+62 ;;=3^Family Hx of Melanoma
+63 ;;^UTILITY(U,$J,358.3,22981,1,4,0)
+64 ;;=4^Z80.8
+65 ;;^UTILITY(U,$J,358.3,22981,2)
+66 ;;=^5063356
+67 ;;^UTILITY(U,$J,358.3,22982,0)
+68 ;;=Z48.817^^76^992^34
+69 ;;^UTILITY(U,$J,358.3,22982,1,0)
+70 ;;=^358.31IA^4^2
+71 ;;^UTILITY(U,$J,358.3,22982,1,3,0)
+72 ;;=3^Surgical Aftercare Skin/Subcutaneous Tissue
+73 ;;^UTILITY(U,$J,358.3,22982,1,4,0)
+74 ;;=4^Z48.817
+75 ;;^UTILITY(U,$J,358.3,22982,2)
+76 ;;=^5063054
+77 ;;^UTILITY(U,$J,358.3,22983,0)
+78 ;;=R99.^^76^992^35
+79 ;;^UTILITY(U,$J,358.3,22983,1,0)
+80 ;;=^358.31IA^4^2
+81 ;;^UTILITY(U,$J,358.3,22983,1,3,0)
+82 ;;=3^Dead Unknown Mortality
+83 ;;^UTILITY(U,$J,358.3,22983,1,4,0)
+84 ;;=4^R99.
+85 ;;^UTILITY(U,$J,358.3,22983,2)
+86 ;;=^5019750
+87 ;;^UTILITY(U,$J,358.3,22984,0)
+88 ;;=Z85.9^^76^992^36
+89 ;;^UTILITY(U,$J,358.3,22984,1,0)
+90 ;;=^358.31IA^4^2
+91 ;;^UTILITY(U,$J,358.3,22984,1,3,0)
+92 ;;=3^Personal Hx of Unspec Neoplasm/Cancer
+93 ;;^UTILITY(U,$J,358.3,22984,1,4,0)
+94 ;;=4^Z85.9
+95 ;;^UTILITY(U,$J,358.3,22984,2)
+96 ;;=^5063452
+97 ;;^UTILITY(U,$J,358.3,22985,0)
+98 ;;=C79.9^^76^992^37
+99 ;;^UTILITY(U,$J,358.3,22985,1,0)
+100 ;;=^358.31IA^4^2
+101 ;;^UTILITY(U,$J,358.3,22985,1,3,0)
+102 ;;=3^Metastatic Cancer Unspec
+103 ;;^UTILITY(U,$J,358.3,22985,1,4,0)
+104 ;;=4^C79.9
+105 ;;^UTILITY(U,$J,358.3,22985,2)
+106 ;;=^5133344
+107 ;;^UTILITY(U,$J,358.3,22986,0)
+108 ;;=Q3014^^77^993^1^^^^1
+109 ;;^UTILITY(U,$J,358.3,22986,1,0)
+110 ;;=^358.31IA^3^2
+111 ;;^UTILITY(U,$J,358.3,22986,1,2,0)
+112 ;;=2^Q3014
+113 ;;^UTILITY(U,$J,358.3,22986,1,3,0)
+114 ;;=3^Telehealth Fac Fee-Pt Site
+115 ;;^UTILITY(U,$J,358.3,22987,0)
+116 ;;=B19.10^^78^994^1
+117 ;;^UTILITY(U,$J,358.3,22987,1,0)
+118 ;;=^358.31IA^4^2
+119 ;;^UTILITY(U,$J,358.3,22987,1,3,0)
+120 ;;=3^Hepatitis B w/o Hepatic Coma
+121 ;;^UTILITY(U,$J,358.3,22987,1,4,0)
+122 ;;=4^B19.10
+123 ;;^UTILITY(U,$J,358.3,22987,2)
+124 ;;=^5000552
+125 ;;^UTILITY(U,$J,358.3,22988,0)
+126 ;;=B17.10^^78^994^2
